Loading ...
drug resistance and the other part of patients(passive) caused bychemotherapy failure
the cancer returned in earlypromptingchemotherapy treatments
stage 4 colon cancer in the cancer returned in earlypromptingchemotherapy treatments
A significant problem ... drug resistancecauseschemotherapy treatments
drug resistancecauseschemotherapy treatments
cancer patients ... drug resistancecauseschemotherapy treatments
to target cells that are abnormally dividing(passive) is designedChemotherapy ( Chemo
mainly(passive) was ... composedpostoperative chemotherapy
to kill fast - growing cells(passive) are designedChemotherapy Chemotherapeutics
to prevent the recurrence of cancer(passive) is mainly designedAdjuvant chemotherapy
oral compromiseresultingfrom radiotherapy , chemotherapy
to prevent recurrence of the disease , particularly distant recurrence(passive) is designedAdjuvant chemotherapy
this phenomenon should be taken into considerationwhen designingantimicrobial chemotherapy
not to cure patients(passive) is designedPalliative chemotherapy
to kill the fast - growing cells of cancer(passive) is designedChemotherapy
to target fast - growing cells , such as cancer(passive) is designedChemotherapy
to kill quickly dividing cells(passive) is designedChemotherapy
Effects on bone from treatment commonmay leadchemotherapy
to kill quickly growing cells(passive) is usually designedChemotherapy
to kill cells that divide quickly(passive) is designedChemotherapy
to kill rapidly dividing cells(passive) is designedChemotherapy
to kill fast - growing cells(passive) is designedChemotherapy
to kill fast - growing cells like blood cells as well as their production(passive) is designedChemotherapy
the factorsinfluencingneoadjuvant chemotherapy
to kill rapidly dividing cancer cells(passive) is designedChemotherapy Chemotherapy
to kill rapidly growing cells such as cancer cells but affects all rapidly growing cells(passive) is designedChemotherapy
to kill fast - growing cancer cells(passive) is designedChemotherapy
the P - gp cells(passive) caused bychemotherapy
to target rapidly dividing cells in a specific stage of cell division(passive) is designedChemotherapy
to study the effect of medication(passive) is designedChemotherapy
to kill rapidly dividing cells throughout the body(passive) is designedChemotherapy
to target active and growing cells(passive) is designedChemotherapy
to target fast growing cancer cells in your body(passive) is designedChemotherapy
to kill cancer cells(passive) is designedChemotherapy
to kill fast - growing cells , like cancer cells(passive) is designedChemotherapy
before surgery(passive) has ... been discoveredNeoadjuvant chemotherapy
to kill rapidly growing cells(passive) however is designedChemotherapy
to destroy the rapidly dividing cells(passive) is designedChemotherapy
to attack rapidly dividing cells(passive) is designedChemotherapy
when used in the metastatic diseasesettingchemotherapy
cardiac and pulmonary toxicitycan causecardiac and pulmonary toxicity
to prolong survival and ease symptoms , but not to cure diseasedesignedto prolong survival and ease symptoms , but not to cure disease
for terminal cancer patients to prolong their survival and ease symptoms of canceris designedfor terminal cancer patients to prolong their survival and ease symptoms of cancer
to prolong survival and ease symptomsdesignedto prolong survival and ease symptoms
in the risk of bleedingresultsin the risk of bleeding
survival in patients withcould influencesurvival in patients with
in only modest prolongation of survival for patients with lung cancerhas resultedin only modest prolongation of survival for patients with lung cancer
to survival in high - risk stage II patientsdid ... contributeto survival in high - risk stage II patients
in patientscould influencein patients
to an increased risk for metabolic syndrome in patients with breast cancermay contributeto an increased risk for metabolic syndrome in patients with breast cancer
to survivaldid ... contributeto survival
to survivalcontributesto survival
in statistically significant improvement in disease - free survivalresultedin statistically significant improvement in disease - free survival
to an increased risk for metabolic syndrome in breast cancer patients and these changes are more profound in pre - menopausal patientsmay contributeto an increased risk for metabolic syndrome in breast cancer patients and these changes are more profound in pre - menopausal patients
to improving survival in some subgroupscan contributeto improving survival in some subgroups
to such improvementcontributedto such improvement
the choice of chemotherapy for the treatment of metachronous metastasesinfluencedthe choice of chemotherapy for the treatment of metachronous metastases
to the patient 's deathledto the patient 's death
significantlycontributessignificantly
to an improvement in both local and distant recurrence with a corresponding improvement in overall survival while chemoradiation only led to an improvement in local recurrence but not distant nor overall survivalledto an improvement in both local and distant recurrence with a corresponding improvement in overall survival while chemoradiation only led to an improvement in local recurrence but not distant nor overall survival
the resultscould influencethe results
in significant improvement in patient survivalresultedin significant improvement in patient survival
to improved survivalwould leadto improved survival
to depression on their ownwould leadto depression on their own
to DFScontributesto DFS
to improved outcomesmay leadto improved outcomes
to a 20 % difference in OS at 5 years compared with observation aloneledto a 20 % difference in OS at 5 years compared with observation alone
in the propagation of residual cancer cellsresultingin the propagation of residual cancer cells
to better chances of survivalcould also contributeto better chances of survival
to down staging of the tumorcould leadto down staging of the tumor
adverse toxic effects such as myelotoxicity , epithelial toxicity , painful hand / foot syndrome and potentially severe cardiac toxicity ( 1causedadverse toxic effects such as myelotoxicity , epithelial toxicity , painful hand / foot syndrome and potentially severe cardiac toxicity ( 1
in some casesresultedin some cases
to prolong survival and ease symptoms , but not cure disease ) or experimental treatmentsdesignedto prolong survival and ease symptoms , but not cure disease ) or experimental treatments
pre - existing priormay causepre - existing prior
the status of EGFR staining in recurrent colorectal cancercould influencethe status of EGFR staining in recurrent colorectal cancer
in partial response in 1 patient , stable disease in 3 patients and progressive diseaseresultedin partial response in 1 patient , stable disease in 3 patients and progressive disease
a condition that he said brings on the worst pain a person can endurehas causeda condition that he said brings on the worst pain a person can endure
in complete resolution of symptomsresultedin complete resolution of symptoms
a patientscould ... influencea patients
thrombuscan causethrombus